Monopar Therapeutics (MNPR)
(Delayed Data from NSDQ)
$63.29 USD
-2.96 (-4.47%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $65.18 +1.89 (2.99%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Monopar Therapeutics Inc. has a market cap of $408.76M, which represents its share price of $66.25 multiplied by its outstanding shares number of 6.17M. As a small-cap company, MNPR's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
MNPR 63.29 -2.96(-4.47%)
Will MNPR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MNPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNPR
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going
MNPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
Here's What Could Help Monopar Therapeutics (MNPR) Maintain Its Recent Price Strength
Other News for MNPR
MNPR forms Boomer Buy Setup on September 20
Jack-in-the-box Bullish appears for MNPR after 0.59% move
MNPR makes New 52 Week Closing High on September 18
New 52 Week Closing High appears for MNPR after 4.61% move
Raymond James Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)